In June 2012, the EMA's CHMP recommended that the marketing authorisation granted to Loraxin [loratadine] in Finland should not be recognised

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1426, 2012-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Refusal of the marketing authorisation for Sumatriptan Galpharm has been confirmed by the EMA's CHMP.

By  

Reactions Weekly, Vol. 1, Iss. 1380, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Safety updates from EMA's CHMP

By  

Reactions Weekly, Vol. 1, Iss. 1360, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Health should be recognised as a human right

By  

Inpharma, Vol. 1, Iss. 1519, 2006-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

The EMA's CHMP is recommending updates to Summary of Product Characteristics (SmPC) of agomelatine [Thymanax, Valdoxan]

By  

Reactions Weekly, Vol. 1, Iss. 1421, 2012-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Generic amlodipine granted marketing approval in Japan.

By  

Inpharma, Vol. 1, Iss. 1634, 2008-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite